BioPorto adjusted EBITDA loss narrows 11% to DKK 16.3 million in Q2 2026; revenue drops 35% to DKK 6.9 million vs Q2 2025
Reuters2026/08/20 05:55- BioPorto posted Q2 revenue of DKK 6.9 million, down 35% year over year, hit by the antibody business divestment and a voluntary recall.
- NGAL revenue slipped 15% to DKK 6.4 million in Q2; adjusted for the recall impact, NGAL revenue totaled DKK 9.2 million.
- Adjusted EBITDA loss narrowed 11% to DKK 16.3 million; cash stood at DKK 75.6 million at June 30.
- Activated a US ProNephro AKI Adult Urine NGAL validation study expanded to about 900 patients; FDA clearance now expected mid-2028.
- Confirmed 2026 outlook: revenue DKK 38-48 million, NGAL revenue DKK 33-42 million, adjusted EBITDA loss DKK 58-68 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
30x Token Speed Challenges GPU Dominance! BNP Paribas Praises Cerebras (CBRS.US) CS-4 for Ushering in the "Wafer-Scale + Decoupled Inference" Era
After AI chip company Cerebras Systems held its Supernova Day event on Tuesday, BNP Paribas stated that the partners and related announcements unveiled by the company left a deep impression on them.
South Korea’s Ruling Party Signals No Further Delay to Crypto Tax
Ethereum Exchange Supply Falls 15% as Bitcoin Balances Rise
CENIT completes share rights offering, raises about EUR 10.9 million
